Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Position Raised by State Street Corp

State Street Corp increased its position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 52.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 22,353 shares of the biotechnology company’s stock after buying an additional 7,680 shares during the quarter. State Street Corp’s holdings in Atara Biotherapeutics were worth $182,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the second quarter valued at $53,000. FMR LLC increased its holdings in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the second quarter valued at $79,000. Finally, Vestal Point Capital LP increased its holdings in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Price Performance

ATRA stock opened at $16.35 on Friday. Atara Biotherapeutics, Inc. has a 52-week low of $6.50 and a 52-week high of $39.50. The company has a 50-day moving average of $11.72 and a two-hundred day moving average of $9.61. The stock has a market capitalization of $94.18 million, a price-to-earnings ratio of -0.63 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the prior year, the company posted ($16.50) EPS. Equities analysts expect that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. RODMAN&RENSHAW raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, December 20th. Canaccord Genuity Group upped their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.